Lecanemab for Alzheimer's disease: Discussing risks and benefits is key

Canada recently approved lecanemab to treat early Alzheimer's disease, but the clinical benefits are modest, it carries a risk of serious adverse effects, and treatment is complex. An article in the Canadian Medical Association Journal provides an overview of the medication and advises health care professionals to engage in shared decision-making with patients and caregivers to help them understand the potential risks and benefits.

Raccontata damedicalxpress.com